Literature DB >> 17513571

Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?

Jörg H W Distler, Oliver Distler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17513571      PMCID： PMC1954675          DOI： 10.1136/ard.2006.067710

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Imatinib for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Werner Seeger; Friedrich Grimminger
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

2.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

3.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

4.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

5.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

6.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

7.  Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.

Authors:  Ricardo T Paniagua; Orr Sharpe; Peggy P Ho; Steven M Chan; Anna Chang; John P Higgins; Beren H Tomooka; Fiona M Thomas; Jason J Song; Stuart B Goodman; David M Lee; Mark C Genovese; Paul J Utz; Lawrence Steinman; William H Robinson
Journal:  J Clin Invest       Date:  2006-09-14       Impact factor: 14.808

8.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Authors:  Hagop Kantarjian; Francis Giles; Lydia Wunderle; Kapil Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245
  8 in total
  5 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

2.  Review of cardiotoxicity in pediatric cancer patients: during and after therapy.

Authors:  Joy M Fulbright
Journal:  Cardiol Res Pract       Date:  2011-05-23       Impact factor: 1.866

Review 3.  Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients.

Authors:  Monika Dudzisz-Śledź; Elżbieta Bylina; Paweł Teterycz; Piotr Rutkowski
Journal:  Drugs Aging       Date:  2021-03-02       Impact factor: 3.923

Review 4.  Cardiotoxicity of Novel Targeted Hematological Therapies.

Authors:  Valentina Giudice; Carmine Vecchione; Carmine Selleri
Journal:  Life (Basel)       Date:  2020-12-11

5.  Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.

Authors:  Paulius Venalis; Britta Maurer; Alfiya Akhmetshina; Nicole Busch; Clara Dees; Michael Stürzl; Jochen Zwerina; Astrid Jüngel; Steffen Gay; Georg Schett; Oliver Distler; Jörg H W Distler
Journal:  J Cell Mol Med       Date:  2009-10       Impact factor: 5.310
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.